Key Takeaways

  • Alcon has launched the Unity Cataract System (CS) in Canada, expanding the company’s next-generation surgical platform ahead of COS 2026 in Montréal
  • The standalone cataract platform is designed to improve surgical efficiency, featuring a phacoemulsification modality that delivers up to two times faster nucleus removal with 40% less energy into the eye

Alcon announced the Canadian launch and availability of the Unity Cataract System (CS), the company’s next-generation standalone cataract surgical platform, ahead of the Canadian Ophthalmological Society (COS) Annual Meeting and Exhibition, taking place June 18–21, 2026, in Montréal.

According to Alcon, the Unity platform has supported more than 285,000 procedures globally across approximately 1,350 systems worldwide. The platform includes both the Unity Cataract System (CS), dedicated exclusively to cataract surgery, and the Unity Vitreoretinal Cataract System (VCS), which supports both cataract and vitreoretinal procedures on a single integrated platform.

“COS 2026 marks an exciting milestone for Alcon as we continue advancing the next generation of surgical innovation in Canada,” said Mark Newson, Country Manager and Head of Surgical, Alcon Canada. “With Unity CS, we are bringing forward technology designed to help surgeons and surgical teams operate with greater efficiency, consistency, and confidence in cataract surgery while supporting a smoother workflow in the operating room.”

The company said Unity CS incorporates a novel phacoemulsification modality engineered to provide up to two times faster nucleus removal while delivering 40% less energy into the eye. The platform also features what Alcon describes as a first-of-its-kind phaco handpiece capable of estimating temperature at the incision site, a feature intended to enhance intraoperative awareness and control.

The Canadian introduction of Unity CS comes amid a broader series of product launches from Alcon in 2026. Recent additions to the company’s portfolio include Unity VCS, PanOptix Pro, and the Valeda photobiomodulation (PBM) device, indicated for the treatment of early and intermediate dry age-related macular degeneration (AMD).

Both Unity VCS and Unity CS are part of the Alcon Vision Suite, the company’s portfolio of products designed to help eye care professionals improve efficiency in both clinical and surgical settings.